Ezra Cohen, Chief Medical Officer of Oncology at Tempus Labs, shared a post on LinkedIn:
“The notable thing about the combination of ficerafusp alpha and pembrolizumab is the rate of deep PR and CR in HPV-negative disease.
These are often the patients who remain disease free for years and likely drove the median OS of close to two years in this study. We await the phase 3 results with excitement.”
Title: Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial
Authors: Glenn Hanna, Dan Zandberg, Deborah Wong, Eric Sherman, Assuntina Sacco, Emrullah Yilmaz, Alberto Hernando-Calvo, Ralf Reiners, David Bohr, Rachel Salazar, Brenda O’Connell, David Raben, Jeltje Schulten, Christine Chung, John Kaczmar
Read the Full Article on Journal of Clinical Oncology
More posts featuring Ezra Cohen.